drugset / Trial / NCT00262327

Safety and Efficacy of Adenoviral Endostatin in the Treatment of Advanced Solid Tumor

NCT00262327 ↗

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The growth and metastasis of solid tumors are dependent on angiogenesis. Endostatin, the C-terminal proteolytic fragment of collagen XVIII, is an effective endogenous angiogenesis inhibitor in cancer therapy in mice. Applied for clinical studies in solid tumor, however, recombinant human endostatin protein, difficulties in a large-scale production of the recombinant endostatin protein, and the cumbersome daily administration. Up to now, its clinical application has been hampered by those matters. We herein constructed a adenoviral vector ecoding human endostatin. This study will test the safety and efficacy of recombinant human endostatin adenovirus (Ad-rhE) in the treatment of patients with advanced solid tumors.

Timeline

Start
2005-05
Primary completion
—
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject E10A Unknown — Other